ES2166328B1 - Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos - Google Patents

Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos

Info

Publication number
ES2166328B1
ES2166328B1 ES200001185A ES200001185A ES2166328B1 ES 2166328 B1 ES2166328 B1 ES 2166328B1 ES 200001185 A ES200001185 A ES 200001185A ES 200001185 A ES200001185 A ES 200001185A ES 2166328 B1 ES2166328 B1 ES 2166328B1
Authority
ES
Spain
Prior art keywords
neurodegenerative
treatment
processes
gsk
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200001185A
Other languages
English (en)
Spanish (es)
Other versions
ES2166328A1 (es
Inventor
Gil Ana Martinez
Martin M Perez
Morera Ana Castro
Munoz Fco Jose Moreno
Jurado Francisco Wandosell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Autonomous University of Madrid
Original Assignee
Consejo Superior de Investigaciones Científicas
Autonomous University of Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas, Autonomous University of Madrid filed Critical Consejo Superior de Investigaciones Científicas
Priority to ES200001185A priority Critical patent/ES2166328B1/es
Priority to GB0030284A priority patent/GB0030284D0/en
Priority to CA2408747A priority patent/CA2408747C/en
Priority to PCT/GB2001/002100 priority patent/WO2001085685A1/en
Priority to KR1020027015132A priority patent/KR100812407B1/ko
Priority to CN2007101010104A priority patent/CN101045715B/zh
Priority to IL15272101A priority patent/IL152721A0/xx
Priority to BR0110734-8A priority patent/BR0110734A/pt
Priority to HU0302002A priority patent/HUP0302002A3/hu
Priority to PL359671A priority patent/PL209780B1/pl
Priority to CNB01812738XA priority patent/CN100358867C/zh
Priority to ES01928117T priority patent/ES2288948T3/es
Priority to PT01928117T priority patent/PT1286964E/pt
Priority to JP2001582286A priority patent/JP4897179B2/ja
Priority to SI200130744T priority patent/SI1286964T1/sl
Priority to AT01928117T priority patent/ATE366238T1/de
Priority to DE60129222T priority patent/DE60129222T2/de
Priority to AU54981/01A priority patent/AU783615B2/en
Priority to RU2002133222/04A priority patent/RU2294931C2/ru
Priority to DK01928117T priority patent/DK1286964T3/da
Priority to EP01928117A priority patent/EP1286964B1/en
Priority to CZ20023692A priority patent/CZ296087B6/cs
Priority to MXPA02011079A priority patent/MXPA02011079A/es
Publication of ES2166328A1 publication Critical patent/ES2166328A1/es
Priority to US10/290,569 priority patent/US6872737B2/en
Application granted granted Critical
Publication of ES2166328B1 publication Critical patent/ES2166328B1/es
Priority to US10/917,175 priority patent/US7666885B2/en
Priority to AU2006200668A priority patent/AU2006200668B2/en
Priority to US11/788,755 priority patent/US7781463B2/en
Priority to CY20071101111T priority patent/CY1106826T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES200001185A 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos Expired - Fee Related ES2166328B1 (es)

Priority Applications (28)

Application Number Priority Date Filing Date Title
ES200001185A ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en) 2000-05-11 2000-12-12 Enzyme inhibitors
DE60129222T DE60129222T2 (de) 2000-05-11 2001-05-11 Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
KR1020027015132A KR100812407B1 (ko) 2000-05-11 2001-05-11 글리코겐 신타제 키나제 ｇｓｋ-3의 헤테로사이클릭 억제제
CN2007101010104A CN101045715B (zh) 2000-05-11 2001-05-11 糖原合酶激酶gsk-3的杂环抑制剂
IL15272101A IL152721A0 (en) 2000-05-11 2001-05-11 Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same
BR0110734-8A BR0110734A (pt) 2000-05-11 2001-05-11 Inibidores heterocìclicos de cinase de sintase de glicogênio gsk-3
HU0302002A HUP0302002A3 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them
PL359671A PL209780B1 (pl) 2000-05-11 2001-05-11 Zastosowanie pochodnych tiadiazolidynodionu do wytwarzania leku
CNB01812738XA CN100358867C (zh) 2000-05-11 2001-05-11 糖原合酶激酶gsk-3的杂环抑制剂
ES01928117T ES2288948T3 (es) 2000-05-11 2001-05-11 Inhibidores heterociclicos del glicogeno sintasa quinasa gsk-3.
PT01928117T PT1286964E (pt) 2000-05-11 2001-05-11 Inibidores heterocíclicos da glicogénio sintase cinase gsk-3
JP2001582286A JP4897179B2 (ja) 2000-05-11 2001-05-11 グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター
SI200130744T SI1286964T1 (sl) 2000-05-11 2001-05-11 Heterocikliäťni inhibitorji glikogenske sintaze kinaze gsk-3
CA2408747A CA2408747C (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
AU54981/01A AU783615B2 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase GSK-3
EP01928117A EP1286964B1 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
PCT/GB2001/002100 WO2001085685A1 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3
DK01928117T DK1286964T3 (da) 2000-05-11 2001-05-11 Heterocykliske inhibitorer glycogensynthasekinase GSK-3
RU2002133222/04A RU2294931C2 (ru) 2000-05-11 2001-05-11 Гетероциклические ингибиторы гликоген-синтазы киназы gsk-3
CZ20023692A CZ296087B6 (cs) 2000-05-11 2001-05-11 Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3
MXPA02011079A MXPA02011079A (es) 2000-05-11 2001-05-11 Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
AT01928117T ATE366238T1 (de) 2000-05-11 2001-05-11 Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
US10/290,569 US6872737B2 (en) 2000-05-11 2002-11-08 Heterocyclic inhibitors of glycogen synthase kinase GSK-3
US10/917,175 US7666885B2 (en) 2000-05-11 2004-08-12 Enzyme inhibitors
AU2006200668A AU2006200668B2 (en) 2000-05-11 2006-02-17 Heterocyclic inhibitors of glycogen synthase kinase GSK-3
US11/788,755 US7781463B2 (en) 2000-05-11 2007-04-20 Enzyme inhibitors
CY20071101111T CY1106826T1 (el) 2000-05-11 2007-08-30 Ετεροκυκλικοι αναστολεις της κινασης συνθασης γλυκογονου gsk-3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001185A ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos

Publications (2)

Publication Number Publication Date
ES2166328A1 ES2166328A1 (es) 2002-04-01
ES2166328B1 true ES2166328B1 (es) 2003-09-16

Family

ID=8493477

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001185A Expired - Fee Related ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos

Country Status (5)

Country Link
JP (1) JP4897179B2 (enExample)
CN (1) CN101045715B (enExample)
ES (1) ES2166328B1 (enExample)
GB (1) GB0030284D0 (enExample)
PT (1) PT1286964E (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
EP2838888B1 (en) * 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors
WO2016149464A1 (en) * 2015-03-17 2016-09-22 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same
CN105330608B (zh) * 2015-10-27 2018-06-26 南方科技大学 脲唑类轴手性化合物及其催化不对称合成方法
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
CN110698380B (zh) * 2019-10-24 2021-01-15 华东理工大学 一种内酰胺衍生物及其制备方法与应用
CN117797146A (zh) * 2020-11-12 2024-04-02 科辉智药生物科技（无锡）有限公司 Sarm1酶活性抑制剂及其在神经退行性疾病中的应用
CN116675653B (zh) * 2022-07-22 2024-10-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863803A (en) * 1957-05-13 1958-12-09 Stauffer Chemical Co Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en) * 1964-11-16 1967-01-31 Olin Mathieson S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de) * 1966-05-23 1970-11-12 Bayer Ag Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en) * 1967-02-10 1975-08-19 Velsicol Chemical Corp New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en) * 1968-05-28 1970-10-13 Velsicol Chemical Corp Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de) * 1971-03-02 1972-09-07 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Substituierte Thiadiazolidindione
JPS58216177A (ja) * 1982-06-10 1983-12-15 Sumitomo Chem Co Ltd フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5532256A (en) * 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
DE4420522A1 (de) * 1994-06-13 1995-12-14 Bayer Ag Bakterizide Thiadiazolidinone
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
JP2002527419A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions

Also Published As

Publication number Publication date
GB0030284D0 (en) 2001-01-24
PT1286964E (pt) 2007-08-08
JP4897179B2 (ja) 2012-03-14
CN101045715B (zh) 2010-11-24
CN101045715A (zh) 2007-10-03
JP2003532708A (ja) 2003-11-05
ES2166328A1 (es) 2002-04-01

Similar Documents

Publication Publication Date Title
ES2166328A1 (es) Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2007001749A1 (es) Compuesto derivado de 2-arilamino-4-(heterociclo)aminopirimidina, inhibidores de la proteina quinasa c-alfa; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes, cancer, enfermedad cardiaca coronaria, aterosclerosis, entre otras.
GB0215844D0 (en) Organic compounds
BRPI0807146B8 (pt) compostos inibidores da atividade da akt, seu uso no tratamento de câncer e artrite, bem como composição farmacêutica compreendendo os mesmos
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
MY162640A (en) Thioninium compounds and their use
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
AP2006003514A0 (en) Piperazine derivatives for the treatment of HIV infections.
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
CR10832A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CR8163A (es) Composicion farmaceutica que contiene un inhibidor de histona desacetilasa
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
GB0226434D0 (en) Combination product
CL2008000254A1 (es) Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
EE200300064A (et) Farmatseutiline kompositsioon C. pneumoniae pooltpõhjustatud infektsioonide raviks ja/või ennetamiseks, mahekompositsioon ja nende kasutamine
CL2009001349A1 (es) Compuestos derivados de urea sustituidos con 1,4-dihidroquinolin-4-ona, inhibidores de adn girasa bacteriana y/o topoisomerasa iv bacteriana; composicion farmceutica; util para el tratamiento de una infeccion bacteriana.
EP1947094A3 (en) Process for the preparation of taxane derivatives
AR011094A1 (es) Medicamento que contiene quinoxalinas en triple combinacion y el uso de quinoxalinas en triple combinacion con inhibidores de proteasas e inhibidoresde transcriptasa como medicamento para el tratamiento del sida y/o de infecciones por hiv

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2166328B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20101018